Leszek Tylicki, Alicja M Debska-Slizien, Slawomir Lizakowski, Milena Przybylska, Zbigniew Heleniak, Marcin Renke, Andrzej L Chamienia, Bogdan Biedunkiewicz, Przemyslaw Rutkowski, Sylwia Małgorzewicz, Boleslaw Rutkowski
BACKGROUND: The renoprotective effects of the direct renin inhibitor, aliskiren, in renal transplant recipients have been supposed, but not finally proven. We performed an exploratory double-blind, losartan controlled, cross-over study to evaluate the influence of aliskiren, direct renin inhibitor, on albuminuria and other surrogate markers of kidney injury in patients after renal transplantation. The safety of this therapy was also evaluated. METHOD: 16 of 18 patients (12 M, 4 F), 48...
2017: Acta Biochimica Polonica